AVBP ▲ +0.8% - ArriVent BioPharma, Inc.
$AVBP - ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
06-OCT-2026 08:04 AM ET
Share this post
More filings for $AVBP
AVBP ▲ +9.3% - ArriVent BioPharma, Inc.Oct 25, 2026AVBP ▲ +2.8% - ArriVent BioPharma, Inc.Oct 20, 2026AVBP ▲ +0.7% - ArriVent BioPharma, Inc.Oct 19, 2026AVBP ▼ -1.5% - ArriVent BioPharma, Inc.Oct 12, 2026AVBP - ArriVent BioPharma, Inc. - SEC Filing Update (08-OCT-2026) | ThinkSabio - Stocks SimplifiedOct 8, 2026$AVBP SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 27, 2026
View full $AVBP filing history →💬 Comments
Loading comments…
Leave a comment